Status:
COMPLETED
Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure
Lead Sponsor:
University Hospital, Brest
Conditions:
Multiple Myeloma
Non-hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
There are limited data concerning the use of biosimilars of filgrastim in autologous stem cell transplantation (ASCT). This study aimed to evaluate G-CSF efficiency and safety (based on haemograms, tr...
Detailed Description
Since 2008, Investigator collected data of all patients who underwent ASCT to treat lymphoma or myeloma. All the patients signed an institutional informed consent form before the harvest of peripheri...
Eligibility Criteria
Inclusion
- patients with DLBCL or multiple myeloma
- patients who underwent ASCT in our hospital
- patients treated by Zarzio® in post-ASCT phase to accelerate the bone marrow recovery
Exclusion
- patients who underwent ASCT but for other diseases
- patients who underwent ASCT for the required diseases but treated with an other biosimilar of Filgrastim
- patients who did not sign the informed consent
Key Trial Info
Start Date :
November 3 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2016
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT03323541
Start Date
November 3 2016
End Date
December 31 2016
Last Update
September 21 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.